Speaker Profile

Ph.D., SVP Clinical Development, Strata Oncology

Biography
Kat Kwiatkowski, PhD, is an Epidemiologist and currently the SVP Clinical Development at Strata Oncology overseeing the functions of Clinical Development & Operations, Medical Affairs, Translational Medicine, and Regulatory. Strata is a precision oncology company committed to accelerating the impact of precision medicine for patients with cancer. Kat led the design and build of two of the largest prospective cohort studies in the world including the Strata Trial (NGS) and the Sentinel Trial (ctDNA recurrence & treatment monitoring). These studies inform the newly designed StrataPATH study, an interventional therapeutic study to advance biomarker hypotheses. Prior to Strata, Kat worked in various Clinical Development roles in both diagnostics and pharma including Affymetrix where she and team were the first to receive FDA clearance for the first whole genome microarray in cytogenetics. Kat is passionate about helping cancer patients get the best personalized care.


 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28


Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.

 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28


  • Dismantling Barriers to Biomarker Testing Through Collaboration (PANEL)
    Session Chair: Omar Perez, AstraZeneca
    - Nikki Martin, LUNGevity
    - Laura J. van ’t Veer, UCSF
    - Jenn Higgins, Guardant Health
    - Kat Kwiatkowski, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care (PANEL)
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
    - Stephen Miller, Blueprint Medicines
  • Immuno-oncology Biomarkers for Predicting Drug Efficacy
    Session Chair: Ronnie Andrews, Oncocyte
    - Paul Billings, Biological Dynamics
    - Kat Kwiatkowski, Strata Oncology
  • Reimagining Oncology - Closing the Gaps between Science and Clinic (PANEL)
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Isma Benattia, Amgen
  • Challenges to Implementing Precision Medicine in the Community Setting (PANEL)
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Vivian Lee, Patient Advocate
    - Kevin B. Knopf, Alameda Health System
    - Christopher Woods, Sutter Health
  • Single Molecule Methylation Profiling of Circulating Tumor DNA
    - Hanlee P. Ji, Stanford
  • Combined Utilization of Precision Medicine Technologies in Primary Clinics
    - Gad Rennert, Carmel Medical Center
  • PMWC Showcase
    - Paul Dempsey, Hawkeye Bio, Inc.